Adjuvant effects of adenylate cyclase toxin of Bordetella pertussis after intranasal immunisation of mice

Vaccine

Volumn 25, Issue 1, 2007, Pages 64-71

  Orr, Barbara ^a   Douce, Gillian ^a   Baillie, Susan ^a   Parton, Roger ^a   Coote, John ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Adenylate cyclase toxin; Bordetella pertussis; Mucosal adjuvant

Indexed keywords

ADENYLATE CYCLASE TOXIN; BACTERIAL TOXIN; ESCHERICHIA COLI LABILE TOXIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; OVALBUMIN; PERTACTIN;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BORDETELLA PERTUSSIS; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; IMMUNIZATION; MONOTHERAPY; MOUSE; NONHUMAN; NOSE SECRETION; PRIORITY JOURNAL;

ADENYLATE CYCLASE TOXIN; ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BORDETELLA PERTUSSIS; FEMALE; IMMUNIZATION; LUNG; MICE; MICE, INBRED BALB C; NOSE; OVALBUMIN; PERTUSSIS VACCINE; T-LYMPHOCYTES; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 33845219554     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.07.019     Document Type: Article

References (34)

1. Decker M.D., and Edwards K.M. Acellular pertussis vaccines. Pediatr Clin North Am 47 (2000) 309-335
2. Goodman Y.E., Wort A.J., and Jackson F.L. Enzyme-linked immunosorbent assay for detection of pertussis immunoglobulin A in nasopharyngeal secretions as an indicator of recent infections. J Clin Microbiol 13 (1981) 286-292
3. Mills K.H.G., Barnard A., Watkins J., and Redhead K. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect Immun 61 (1993) 399-410
4. Tuomanen E.I., Zapiain L.A., Galvan P., and Hewlett E.L. Characterisation of antibody inhibiting adherence of Bordetella pertussis to human respiratory epithelial cells. J Clin Microbiol 20 (1984) 167-170
5. Thomas M.G., Ashworth E.L.A., Miller E., and Lambert H.P. Serum IgG, IgA and IgM responses to pertussis toxin, filamentous haemagglutinin and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell vaccine. J Infect Dis 160 (1989) 838-845
6. Redhead K., Watkins J., Barnard A., and Mills K.H.G. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect Immun 61 (1993) 3190-3198
7. Mills K.H.G. Immunity to Bordetella pertussis. Microbes Infect 3 (2001) 655-677
8. Shahin R.D., Amsbaugh D.F., and Leef M.F. Mucosal immunization with filamentous haemagglutinin protects against Bordetella pertussis respiratory infection. Infect Immun 60 (1992) 1482-1488
9. Roberts M., Cropley I., Chatfield S., and Dougan G. Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P.69 and FHA. Vaccine 11 (1993) 866-872
10. Cropley I., Douce G., Roberts M., Chatfield S., Pizza M., Marsili I., et al. Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: effects of formaldehyde treatment. Vaccine 13 (1995) 1643-1648
11. Cahill E.S., O'Hagan D.T., Illum L., Barnard A., Mills K.H.G., and Redhead K. Immune responses and protection against Bordetella pertussis after by intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. Vaccine 13 (1995) 455-462
12. Isaka M., Yasuda Y., Taniguchi T., Kosuka S., Matano K., Maeyama J., et al. Mucosal and systemic antibody responses against an acellular pertussis vaccine after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant. Vaccine 21 (2003) 1165-1173
13. Roberts M., Bacon A., Rappuoli R., Pizza M., Cropley I., Douce G., et al. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins. Infect Immun 63 (1995) 2100-2108
14. Pizza M., Giuliani M.M., Fontana M.R., Monaci E., Douce G., Dougan G., et al. Mucosal vaccines: non toxic forms of LT and CT as mucosal adjuvants. Vaccine 19 (2001) 2534-2541
15. Ryan E.J., McNeela E., Murphy G.A., Stewart H., O'Hagan D., Pizza M., et al. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect Immun 67 (1999) 6270-6280
16. Goodwin M.S., and Weiss A.A. Adenylate cyclase toxin is critical for lethal infection by Bordetella pertussis in infant mice. Infect Immun 58 (1990) 3445-3447
17. Guermonprez P., Khelef N., Blouin E., Rieu P., Ricciardi-Castagnoli P., Guiso N., et al. The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha(M)beta(2) integrin (CD11b/CD18). J Exp Med 193 (2001) 1035-1044
18. Gueirard P., Druilhe A., Pretolani M., and Guiso N. Role of adenylate cyclase-hemolysin in alveolar macrophage apoptosis during Bordetella pertussis infection in vivo. Infect Immun 66 (1998) 1718-1725
19. Weingart C.L., Mobberley-Schuman P.S., Hewlett E.K., Gray M.C., and Weiss A.A. Neutralising antibodies to adenylate cyclase toxin promote phagocytosis of Bordetella pertussis by human neutrophils. Infect Immun 68 (2000) 7152-7155
20. Arciniega J.L., Hewlett E.L., Johnson F.D., Deforest A., Wassilak A., Onorato I.M., et al. Human serological responses to envelope associated proteins and adenylate cyclase toxin of Bordetella pertussis. J Infect Dis 163 (1991) 135-142
21. Betsou F., Sebo P., and Guiso N. CyaC mediated activation is important not only for toxic but also for protective activities of Bordetella pertussis adenylate cyclase-hemolysin. Infect Immun 61 (1993) 3583-3589
22. Farfel Z., Konen S., Wiertz E., Klapmuts R., Addy P.A.K., and Hanski E. Antibodies to Bordetella pertussis adenylate cyclase are produced in man during pertussis infection and after vaccination. J Med Microbiol 32 (1990) 173-177
23. Cherry J.D., Xing D., Newland P., Patel K., Heininger U., and Corbel M.J. Determination of serum antibody to Bordetella pertussis adenylate cyclase toxin in vaccinated and unvaccinated children and in children and adults with pertussis. Clin Infect Dis 38 (2004) 502-507
24. Guiso N., Szatanik M., and Rocancourt M. Protective activity of Bordetella adenylate cyclase-hemolysin against bacterial colonisation. Microb Pathog 11 (1991) 423-431
25. Hormozi K., Parton R., and Coote J.G. Adjuvant and protective properties of native and recombinant Bordetella pertussis adenylate cyclase toxin preparations in mice. FEMS Immunol Med Microbiol 23 (1999) 273-282
26. Ross P.J., Lavelle E.C., Mills K.H., and Boyd A.P. Adenylate cyclase toxin from Bordetella pertussis synergizes with lipopolysaccharide to promote innate interleukin-10 production and enhances the induction of Th2 and regulatory T cells. Infect Immun 72 (2004) 1568-1579
27. MacDonald-Fyall J., Xing D., Corbel M., Baillie S., Parton R., and Coote J.G. Adjuvanticity of native and detoxified adenylate cyclase toxin of Bordetella pertussis towards co-administered antigens. Vaccine 22 (2004) 4270-4281
28. Westrop G.D., Hormozi E.K., da Costa N.A., Parton R., and Coote J.G. Bordetella pertussis adenylate cyclase toxin: proCyaA and CyaC proteins synthesised separately in Escherichia coli produce active toxin in vitro. Gene 180 (1996) 91-99
29. Douce G., Fontana M., Pizza M., Rappuoli R., and Dougan G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect Immun 65 (1997) 2821-2828
30. Beckerman K.P., Rogers H.W., Corbett J.A., Schreiber R.D., McDaniel M.L., and Unanue E.R. Release of nitric oxide during the T-cell independent pathway of macrophage activation. J Immunol 150 (1993) 888-895
31. Giuliani M.M., Giudice G.D., Giannelli V., Dougan G., Douce G., Rappuoli R., et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med 187 (1998) 1123-1132
32. Lycke N. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM. Cell Microbiol 6 (2004) 23-32
33. Boyd A.P., Ross P.J., Conroy H., Mahon N., Lavelle E.C., and Mills K.H. Bordetella pertussis adenylate cyclase toxin modulates innate and adaptive immune responses: distinct roles for acylation and enzymatic activity in immunomodulation and cell death. J Immunol 175 (2005) 730-738
34. El Idrissi M.E., Ladant D., and Leclerc C. The adenylate cyclase of Bordetella pertussis: a vector to target antigen presenting cells. Toxicon 40 (2002) 1661-1665